US FDA inspects plants owned by Laurus Labs, Sun Pharma, Torrent Pharma, and Dr. Reddy's

7 Dec 2023 , 10:56 AM

According to CNBC TV 18 report, the US Food and Drug Administration (US FDA) is now inspecting facilities owned by Indian pharmaceutical corporations, such as Dr. Reddy’s, Sun Pharma, Torrent Pharma, and Laurus Labs.

Torrent Pharma’s oncology facility, Laurus Labs’ Vizag facility, Sun Pharma’s Dadra facility, and Dr. Reddy’s R&D Centre in Hyderabad are among the pharmaceutical facilities that are presently undergoing inspections, according to the business television report.

The US FDA carried out a pre-approval inspection (PAI) at the oral cancer manufacturing facility of Torrent Pharmaceuticals in Bileshwarpura, Gujarat, in March. The USFDA issued a Form 483 after the inspection, which usually includes the observations made during the inspection. In this instance, the manufacturing facility in Gujarat made one observation.

Dadra is home to a Sun Pharma formulations manufacturing facility.

A fall in the US was offset by a spike in sales from operations in Brazil, Germany, and India, which helped Torrent Pharma post a 24% increase in net profit for the second quarter, to Rs 386 crore, on December 4.

On October 20, Laurus Laboratories said that its consolidated net profit for the July–September quarter of the current fiscal year had decreased by 84.1% year over year to Rs 37.12 crore.

On October 27, Dr Reddy’s Laboratories said that its consolidated net profit for the July–September quarter was Rs 1,480 crore, up 33% year over year (YoY). This was the company’s highest-ever net profit.

Sun Pharma had earlier announced a 5% year-over-year increase in consolidated net profit for the current fiscal year’s July–September quarter, coming in at Rs 2,375.5 crore.

For feedback and suggestions, write to us at [e-mail]